| Literature DB >> 35035733 |
Lívia Moreira Genaro1, Luís Eduardo Miani Gomes1, Ana Paula Menezes de Freitas Franceschini1, Hugo Dugolin Ceccato1, Rafael Nascimento de Jesus1, Amanda Pereira Lima1, Cristiane Kibune Nagasako2, João José Fagundes1, Maria de Lourdes Setsuko Ayrizono1, Raquel Franco Leal1.
Abstract
Inflammatory bowel diseases are chronic illnesses that involve intestinal inflammation and are usually diagnosed as Crohn's disease or ulcerative colitis. As these diseases do not have a cure, the goal of treatment is to induce and maintain remission. Monoclonal antibodies have been recognized as the most advanced therapy to avoid complications and reduce the need for surgical approaches. However, although their effectiveness has been proven by several studies, they can trigger the immune system, induce the occurrence of immunogenicity, which may lead to the loss of response and treatment failure. The purpose of this review is to determine what are the main mechanisms involved in IBD; to assess the recommended treatments; to explore the mechanisms of immunogenicity. We also try to explain the detection and describe the existing advances that make possible the clinical application of these approaches. AJTREntities:
Keywords: Crohn’s disease; Inflammatory bowel disease; immunogenicity; monoclonal antibodies; ulcerative colitis
Year: 2021 PMID: 35035733 PMCID: PMC8748125
Source DB: PubMed Journal: Am J Transl Res ISSN: 1943-8141 Impact factor: 4.060